cosunter【300436】
400-887-5001 |  中文 | 
Home News Direct Acting Antiviral Therapy and Tumor Recurrence after Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma

Direct Acting Antiviral Therapy and Tumor Recurrence after Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma

Published:2016-07-05 | Source:Journal of Hepatology | Visited:1045

Ju Dong Yang, Bashar A. Aqel, Surakit Pungpapong, Gregory J. Gores, Lewis R. Roberts,Michael D. Leise

Abstract

We read with great interest the article by Reig et al., published in Journal of Hepatology, which reported the impact of direct acting antivirals (DAA) on the risk of hepatocellular carcinoma (HCC) recurrence after achievement of complete radiological response by resection, ablation or chemoembolization.A surprisingly high recurrence rate was noted after DAA treatment: 16 (27.6%) of 58 patients developed radiologic tumor recurrence after a median follow up of only 5.7 months. The authors hypothesized that rapid eradication of HCV virus may have affected immune cancer surveillance, which could have led to a sudden increase in cell proliferation without the counterbalance of immune-induced cell death.